Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)



Status:Recruiting
Conditions:Dermatology, Dermatology, Hair Loss
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - 49
Updated:4/21/2016
Start Date:March 2016
End Date:April 2017
Contact:Clincial Trials Registry Team
Email:IR-CTRegistration@Allergan.com

Use our guide to learn which trials are right for you!

Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men

This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients
with androgenetic alopecia (AGA).


Inclusion Criteria:

- Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss
for at least 1 year

Exclusion Criteria:

- History of Paget's disease, osteoporosis, or bone malignancy

- History of bone fracture within the previous 12 months, except for metatarsal,
metacarpal, or skull fractures

- Patient is currently undergoing radiation therapy or anticipates undergoing radiation
therapy at any time during the study

- Drug or alcohol abuse within 12 months

- HIV positive

- Received hair transplants or had scalp reductions

- Use of hair weaves, hair extensions or wigs within 3 months

- Application of topical medications, minoxidil or nonsteroidal anti-inflammatory drugs
(NSAIDs) to scalp within 4 weeks
We found this trial at
3
sites
Lynchburg, Virginia 24501
?
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Austin, Texas 78759
?
mi
from
Austin, TX
Click here to add this to my saved trials
College Station, Texas 77845
?
mi
from
College Station, TX
Click here to add this to my saved trials